JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification

Tokyo, Japan – September 17, 2024 –JSR Life Sciences, a JSR Group company, today announced the launch of its next generation protein A chromatography resin, Amsphere™ A+. The resin will be presented at the BioProcess International Conference & Exhibition (BPI) 2024, September 23-26, 2024, in Boston, USA and at BioJapan to be held at Pacifico Yokohama from October 9-11, 2024.

Amsphere™ A+ uses a proprietary protein ligand and advanced polymer technology to significantly outperform its predecessor, Amsphere™ A3, in terms of binding capacity, alkali stability and pressure-flow property, resulting in improved efficiency of the production process.

Antibody drugs have become widely used as effective therapies for cancer and intractable diseases with high efficacy and minimal side effects. The production processes for these drugs are becoming highly sophisticated and complex due to the commercialization of bispecific antibodies and antibody-drug conjugates. With Amsphere™ A+, high reliability and improved production efficiency can be expected in the antibody drug manufacturing process.

Launched in 2016, Amsphere™ A3 has been well received in the market and used in more than 150 protein therapeutics manufacturing programs including commercial phase production. JSR Life Sciences also provides best-in-class research products and services to its partners for drug discovery, development and manufacturing through its unique products, services, and globally operating affiliates.

JSR Life Sciences will respond promptly to the needs of the global market with its unique products and services providing a complete offering from research through commercialization and technical support.